Long-term outcomes with haloperidol versus placebo in acutely admitted adult ICU patients with delirium.

"Declarations Conflicts of interestAG, MBNK, MOC and AP are affiliated with the Department of Intensive Care at Rigshospitalet, which has received funding for other projects from The Novo Nordisk Foundation, Pfizer, and Fresenius Kabi, Sygeforsikringen “danmark”. AP has received an honorarium from Novartis for the participation in an advisory board. AP is on DSMB for The Mega-Rox trial, UK-Rox trial, Bone Zone trial. BSR are affiliated with the Department of Anaesthesia and Intensive Care, Aalborg University Hospital, Aalborg, Denmark, which has received funding for other project from Novo Nordisk Foundation, Danish Ministry of Education and Science and Beckett Foundation. MHB are affiliated with the Department of Anaesthesia and Intensive Care at Copenhagen University Hospital – North Zealand, which has received funding for other research projects from The Novo Nordisk Foundation, Sygeforsikringen “danmark”, Toyota Foundation, A.P. Moeller Foundation, Frimodt-Heineke Foundation, Svend Andersen Foundation, Ehrenreich Foundation, and Olga Bryde Nielsen Foundation, and has conducted contract research for AM-Pharma (the REVIVAL trial) and Inotrem (ASTONISH trial). MHB has received an honorarium from AM-Pharma for participation in an advisory board. TL is a member of DSMB for Novo Nordisk and Leo Pharma study. BE is part of the Advisory Board of Eli Lilly Denmark A/S, Janssen-Cilag, Lundbeck Pharma A/S, and Takeda Pharmaceutical Company Ltd; and has received lecture fees from Bristol-Myers Squibb, Boehringer Ingelheim, Otsuka Pharma Scandinavia AB, Eli Lilly Company, and Lundbeck Pharma A/S. JH has received funding from Paulo foundation, Finska Läkaresällskapet, NordForsk and Tor och Kirsti Johanssons Hjärt och Cancerstiftelse. GC has received istituational research grants from Neuroptics and Integra and is a board member at Neuroptics, Integra, Biogen, Invex Therapeutics and Idorsia. All other authors have no conflicts to disclose. Conflicts of interest AG, MBNK, MOC and AP are affiliated with the Department of Intensive Care at Rigshospitalet, which has received funding for other projects from The Novo Nordisk Foundation, Pfizer, and Fresenius Kabi, Sygeforsikringen “danmark”. AP has received an honorarium from Novartis for the participation in an advisory board. AP is on DSMB for The Mega-Rox trial, UK-Rox trial, Bone Zone trial. BSR are affiliated with the Department of Anaesthesia and Intensive Care, Aalborg University Hospital, Aalborg, Denmark, which has received funding for other project from Novo Nordisk Foundation, Danish Ministry of Education and Science and Beckett Foundation. MHB are affiliated with the Department of Anaesthesia and Intensive Care at Copenhagen University Hospital – North Zealand, which has received funding for other research projects from The Novo Nordisk Foundation, Sygeforsikringen “danmark”, Toyota Foundation, A.P. Moeller Foundation, Frimodt-Heineke Foundation, Svend Andersen Foundation, Ehrenreich Foundation, and Olga Bryde Nielsen Foundation, and has conducted contract research for AM-Pharma (the REVIVAL trial) and Inotrem (ASTONISH trial). MHB has received an honorarium from AM-Pharma for participation in an advisory board. TL is a member of DSMB for Novo Nordisk and Leo Pharma study. BE is part of the Advisory Board of Eli Lilly Denmark A/S, Janssen-Cilag, Lundbeck Pharma A/S, and Takeda Pharmaceutical Company Ltd; and has received lecture fees from Bristol-Myers Squibb, Boehringer Ingelheim, Otsuka Pharma Scandinavia AB, Eli Lilly Company, and Lundbeck Pharma A/S. JH has received funding from Paulo foundation, Finska Läkaresällskapet, NordForsk and Tor och Kirsti Johanssons Hjärt och Cancerstiftelse. GC has received istituational research grants from Neuroptics and Integra and is a board member at Neuroptics, Integra, Biogen, Invex Therapeutics and Idorsia. All other authors have no conflicts to disclose."

"Funding Open access funding provided by Lund University. The AID-ICU trial is funded by The Innovation Fund Denmark, Zealand Region Research Fund, Foght Foundation, Hindsgavl Intensive Care Symposium, and the Regions of Denmark Medical Research Fund. The funders had no influence on trial design, conduct, or report. This research was supported by Innovationsfonden (Grant 4108-00011B)."